Toggle navigation
About Us
Business Areas
R & D
Manufacturing
Beyond Business
Investors
Careers
Contact Us
Investors
Investors > FY 2017-18
Overview
Chairman's Statement
Shareholder Information
Policies or Statutory Documents
IEPF
Debentures
Amalgamation
MOA/AOA
Procedure for Dematerialisation of Shares
Archives
Credit Ratings
CSR
AGM Transcript
Annual Return
Disclosures under Regulation 46 and 62 of SEBI LODR
Financial
2022-23
2021-22
2020-21
2019-20
2018-19
2017-18
2016-17
2015-16
2014-15
2013-14
2012-13
2011-12
Investors > FY 2017-18
1. Annual Report
Annual Report
Torrent Pharma Inc
Bio-Pharm Inc.
Torrent Do Brasil Ltd
Heumann Pharma GmbH
Heunet Pharma GmbH
Norispharm GmbH
Torrent Pharma GmbH
Torrent Pharma Philippines Inc
Zao Torrent Pharma
Torrent Pharma S.R.L.
Torrent Pharma (UK) Ltd
Laboratorios Torrent, S.A. de C.V.
Laboratories Torrent Malaysia Sdn. Bhd.
Torrent Australasia Pvt. Ltd
Torrent Pharma (Thailand) Co. Ltd.
Torrent Pharma France S.A.S
Aptil Pharma Limited
2. Intimation to Stock Exchange
45th AGM Chairman Result and Scrutinizer's Report
Proceedings of 45th Annual General Meeting of the Company held on 2nd August, 2018
Newspaper Notice of 45th AGM and E-voting procedure
Stock Exchange Intimation of 45th AGM
Newspaper Advertisement of Book Closure (Gujarati)
Payment of Interest & Redemption on Secured Redeemable Non Convertible Debentures (NCDs)
Newspaper Advertisement of Book Closure (English)
Newspaper Advertisement of Financial Results for Q4 2017-18
Intimation for Book Closure
Intimation for Presentation to analysts on audited Financial Results for the quarter and year ended 31st March, 2018
Intimation for Concall with Investors / Analysts- Q4 2017-18
Intimation for Concall with Investors / Analysts- Q3 2017-18
Intimation for Concall with Investors / Analysts- Q2 2017-18
Intimation for Concall with Investors / Analysts- Q1 2017-18
Newspaper Advertisement of BM Notice - 30-05-2018
Intimation of the Board Meeting dated 30-05-2018
Shareholding Pattern Q4
Shareholding Pattern Q3
Intimation for Presentation to analysts on un-audited Consolidated Financial Results for the quarter and nine months ended 31st December, 2017
Payment of Interest & Redemption on Secured Redeemable Non-Convertible Debentures (NCDs)
Postal Ballot Result and Scrutinizer's Report - 28th February, 2018
Torrent & Novo Nordisk India expand insulin manufacturing facility at Indrad
Torrent Pharmaceuticals Limited completes the acquisition of branded formulation business of Unichem
Torrent Pharma acquires Bio-Pharm, Inc.
Stock Exchange intimation for newspaper advertisement for completion of dispatch of Postal Ballot Notice & Form
Newspaper Advertisement of BM notice - 8th February, 2018
Closure of Trading Window
Intimation of the date of Board Meeting
Intimation of the date of Board Meeting
Intimation regarding issue of Non-Convertible Debentures on Private Placement basis
Intimation for Presentation to analysts on un-audited Consolidated Financial Results for the quarter and half year ended 30th September, 2017
Torrent Pharma acquires Branded Formulation Business of India and Nepal of Unichem Laboratories Limited
Compliances under Regulation 52(4) of SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 for half year ended 30th September, 2017
Newspaper Advertisement of Financial Results for Q2 2017-18
Intimation of the date of Board Meeting
Newspaper Advertisement of BM notice - 3rd November, 2017
Shareholding Pattern Q2
Shareholding Pattern Q1
Intimation of Voting Results of 44th AGM under Regulation 44(3) of SEBI (LODR)
44th AGM Chairman Result and Scrutinizer Report
Newspaper Advertisement of Financial Results for Q1 2017-18
Intimation for presentation to Analysts on Un-Audited Consolidated Financial Results for the quarter ended 30th June, 2017
Intimation of Resignation of Director of Company
Newspaper advertisement of BM notice - 31st July 2017
Intimation of the date of Board Meeting 31st July, 2017
3. Quarterly Results
Q1 17-18
Q2 17-18
Q3 17-18
Q4 17-18
Revenue Update
Press Release on Q1 Results
Q1, FY 2018 Con call Transcript
Stand Alone Results
Consolidated Results
Revenue Update
Press Release on Q2 Results
Standalone Results
Consolidated Results
Q2, FY 2018 Con call Transcript
Revenue Update
Consolidated Results
Stand Alone Results
Q3, FY 2018 Con Call Transcript
Press Release on Q3 Results
Q4,FY 2018 Con Call Transcript
Revenue Q4 & FY - 17-18
Press Release on Q4 Results
Standalone Results
Consolidated Results
Details of Nodal Officer
Name
: Chintan Trivedi
Designation
: Company Secretary
E-mail Id
: investorservices@torrentpharma.com
IEPF Authority - Refund web page
IEPF Authority - Refund web page >>